Emma Walmsley, GSK CEO (MediaPunch Inc/Alamy)

FDA ap­proves GSK's JAK in­hibitor for rare blood can­cer af­ter three-month de­lay

The FDA ap­proved a new JAK in­hibitor, mo­melo­tinib, from GSK for adults with the rare bone mar­row can­cer myelofi­bro­sis who al­so have ane­mia. The ap­proval …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.